Background
Antibody-dependent cellular cytotoxicity (ADCC) by NK cells can be augmented by equipping them with the ADAM-17 resistant high-affinity Fc receptor, CD64, but poor persistence and limited scale to generate large number of NK cells for immunotherapy have constrained translation. Whether HIV-BNAb directed ADCC through CD64 could be improved via inclusion of alternative signaling domains also remained undetermined. Here, we have developed an approach to gene-modify NK cells after feeder cell expansion with the full-length CD64 gene sequence or Fc receptor chimeric molecules possessing the extracellular portion of CD64 fused with the direct Fc-receptor signaling domain of CD32.
Methods
Primary human NK cells from peripheral blood were expanded to scale (>100-fold per round of incubation with irradiated K562-mbIL-21 feeder cells) and engineered to express CD64 constructs by mRNA electroporation (~95% surface CD64 expression) or lentiviral transduction (~75%). Expanded NK expressing full-length CD64 or CD64/CD32 chimeras were then pre-loaded with HIV-specific BNAbs to measure antibody retention by Flow Cytometry followed by ADCC functional assays against HIV-1 infected autologous CD4+ primary T cells including 4-hour CD107a degranulation assays or 24-hour HIV p24 intra-cellular capsid expressing target elimination assays.
Results
CD64 engineered NK cells bound HIV-specific bnAbs at markedly higher levels than control NK cells (~15,000-fold increase in geometric mean fluorescence) and retained surface-bound antibody for for 4 days following electroporation or 8 days following lentiviral transduction (vs ~4 hours in control NK cells expressing only CD16). Full-length CD64 engineered NK cells showed significantly greater ADCC than controls or CD64/CD32 chimera NK cells, with higher degranulation and enhanced elimination of HIV-infected targets following bnAb pre-loading. Importantly, even after a 24-hour ADCC challenge, CD64 NK cells resisted receptor downregulation, maintained bnAb loading, and remained viable indicating potential for sequential killing without re-arming. Chimeric CD64/CD32 receptors retained strong antibody binding but did not provide superior ADCC over intact CD64 in spite of having direct signaling capacity via a CD32 ITAM domain.
Conclusions
We demonstrate scalable manufacture level expansion and genetic modification of full-length Fc receptor engineered human NK cells that support advancing CD64 “antibody-armored” autologous NK immunotherapy strategies toward a HIV cure.